Reverse DCF
What growth does the market imply for PPLPHARMA?
Working backwards from the current price to find the FCF growth assumption baked in.
very aggressive
26.3% implied annual FCF growth
The market is pricing in exceptional growth that only a handful of companies sustain for a decade. For context, this company has historically grown at 20.0%. High execution risk.
Current Price
₹147
Historical Growth
20.0%
FCF Yield
1.17%
Price / FCF
85.1x
Plain English
To justify today's price of $146.61, PPLPHARMA.NS needs to grow its free cash flow at 26.2% per year for the next 10 years. That is 6.2% faster than its historical growth rate of 20.0%. At its historical growth rate, the stock would take 15 years to justify today's price. The market is effectively paying for a perfect future.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| GDP rate | 10.0% | ₹17 | -88.7% |
| Half implied | 13.1% | ₹31 | -79.0% |
| Historical | 20.0% | ₹78 | -47.0% |
| Implied | 26.3% | ₹147 | +0.5% |
At Historical Growth Rate
It would take 15 years for PPLPHARMA to organically grow into today's price assuming its historical FCF growth of 20.0%.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, Monte Carlo, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.